Acadia Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval for Nuplazid, which the FDA said is the first drug it has approved to treat psychosis associated with Parkinson’s disease.
WSJ.com: Health, Wall Street Journal: Business: Health
Fri, 04/29/2016 - 5:08pm
Acadia Pharmaceuticals Inc. has received U.S. Food and Drug Administration approval for Nuplazid, which the FDA said is the first drug it has approved to treat psychosis associated with Parkinson’s disease.